Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects

Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects - Detecting sympathetic denervation and regional myocardial inflammation in patients with cardiac involvement sarcoidosis (CANVAS study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006533

Enrollment

Registered

2011-10-30

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcoidosis

Interventions

All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Ec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sarcoidosis patient with and without cardiac involvement will be enrolled from the first department of Internal Medicine, Hokkaido University Hospital. Patients with sarcoidosis met the diagnostic criteria for cardiac sarcoidosis based on Japanese Ministry of Health and Welfare. Patients without cardiac involvement of sarcoidosis will serve as control. Age less than 20 when their guardian agrees with the entry.

Exclusion criteria

Exclusion criteria: Patients with coronary artery disease Patients with underlying dilated cardiomyopathy or other cardiomyopathies Life expectancy less than 1 year due to other co-morbidity Inability to obtain informed consent pregnant or breast-feeding Claustrophobia

Design outcomes

Primary

Measure	Time frame
Echo and MRI for evaluating LV function. SAECG and AECG for evaluating arrhythmia. Positron emission tomography: 11C Hydroxyephedrine PET for evaluating myocardial sympathetic nervous function. 18-F fluorodeoxyglucose PET for evaluating myocardial and systemic inflammation. 15O labeled water for evaluating myocardial blood flow and coronary resistance. biomarkers from blood samples.	—

Countries

Japan

Contacts

Public ContactKeiichiro Yoshinaga, M.D., Ph.D, F.A.C.C..

Hokkaido University Graduate School of Medicine, Department of Photobiology

kyoshi@med.hokudai.ac.jp011-706-5152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026